Selpercatinib, a first-in-class, highly selective, and potent RET kinase inhibitor with CNS activity, was approved in the United States for the treatment of RET-activated, advanced, or metastatic lung and thyroid cancers [12,13]. This evidence concerns the gene RET and thyroid gland carcinoma.